Lessons learned from 20 years of preclinical testing in pediatric cancers

Area of Science:

• Pediatric Oncology
• Cancer Drug Development
• Preclinical Research

Background:

• Targeted cancer agents for adult malignancies are more numerous than those for pediatric cancers.
• Distinctive biology and small patient populations pose challenges for pediatric cancer drug development.
• Genomic sub-classification further complicates pediatric cancer drug development.

Purpose of the Study:

• To review and summarize lessons learned from two decades of National Cancer Institute (NCI)-supported preclinical testing of targeted cancer agents in pediatric cancer models.
• To aid the pediatric research community in identifying promising agents for clinical testing.

Main Methods:

• Review of efficacy testing results from NCI-supported preclinical pediatric programs.
• Analysis of data from over 100 agents tested in murine models of childhood cancers.

Main Results:

• Publication of both positive and negative efficacy results for over 100 agents.
• Identification of key challenges and lessons in preclinical pediatric cancer drug development.

Conclusions:

• Two decades of NCI-supported preclinical research provide valuable insights into pediatric cancer drug development.
• Prioritization of agents for clinical evaluation in children is crucial due to limited patient populations.
• Sharing of preclinical data is essential for advancing pediatric oncology.